Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.68 |
| ▸ | POLB | P06746 | 3/20 | 0.63 |
| ▸ | MAPT | P10636 | 4/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1045292 | 0.87 | SIRT6 (0.69) | SIRT6POLBMAPTALDH1A1LMNA | |
| SCHEMBL6151230 | 0.86 | SIRT6 (0.81) | SIRT6POLBMAPTALDH1A1LMNA | |
| SCHEMBL15271381 | 0.86 | SIRT6 (0.81) | SIRT6POLBMAPTALDH1A1LMNA | |
| SCHEMBL6945690 | 0.84 | SIRT6 (0.65) | SIRT6POLBMAPTALDH1A1LMNA | |
| SCHEMBL25797013 | 0.83 | SIRT6 (0.59) | SIRT6POLBMAPTALDH1A1LMNA | |
| SCHEMBL943807 | 0.83 | SIRT6 (0.62) | SIRT6POLBMAPTALDH1A1LMNA | |
| SCHEMBL5741339 | 0.83 | SIRT6 (0.62) | SIRT6POLBMAPTALDH1A1LMNA | |
| SCHEMBL27580383 | 0.83 | SIRT6 (0.62) | SIRT6POLBMAPTALDH1A1LMNA | |
| SCHEMBL2730000 | 0.82 | KDM4E (0.63) | SIRT6POLBMAPTALDH1A1LMNA | |
| SCHEMBL10511652 | 0.82 | LMNA (0.68) | SIRT6POLBMAPTALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1257896-C | Funcitonal molecule material containing four tertiary amine branches and preparation method | UNIV FUDAN (CN) | 2006-05-31 | — | — | CN | claimed |
| CN-1539833-A | Funcitonal molecule material containing four tertiary amine branches and preparation method | 复旦大学 | 2004-10-27 | — | — | CN | claimed |
| EP-4676486-A1 | METHODS OF TREATING SKELETAL DYSPLASIAS | QED Therapeutics, Inc. (US) | 2026-01-14 | — | — | EP | disclosed |
| US-12357632-B2 | Methods of treating cholangiocarcinoma | QED THERAPEUTICS, INC. (US) | 2025-07-15 | — | — | US | disclosed |
| WO-2025090870-A1 | INFIGRATINIB AND METABOLITES THEREOF FOR USE IN METHODS OF TREATING SKELETAL DISORDERS | QED THERAPEUTICS, INC. (US) | 2025-05-01 | — | — | WO | disclosed |
| US-20250101002-A1 | DEUTERATED INFIGRATINIB COMPOUNDS | Ferro Therapeutics, Inc. | 2025-03-27 | — | — | US | disclosed |
| WO-2024186882-A1 | METHODS OF TREATING SKELETAL DYSPLASIAS | QED THERAPEUTICS, INC. (US) | 2024-09-12 | — | — | WO | disclosed |
| WO-2024093681-A1 | USE OF INFIGRATINIB IN TREATING GASTRIC CANCER AND ADENOCARCINOMA | QED医药股份有限公司 | 2024-05-10 | — | — | WO | disclosed |
| CN-117982507-A | Use of inflictinib in the treatment of gastric and adenocarcinoma | QED医药股份有限公司 | 2024-05-07 | — | — | CN | disclosed |
| US-20240009193-A1 | METHODS OF TREATING ACHONDROPLASIA | CALCILYTIX THERAPEUTICS INC. | 2024-01-11 | — | — | US | disclosed |
| EP-4262774-A1 | METHODS OF TREATING ACHONDROPLASIA | QED Therapeutics, Inc. (US) | 2023-10-25 | — | — | EP | disclosed |
| US-7071216-B2 | Substituted benz-azoles and methods of their use as inhibitors of Raf kinase | CHIRON CORPORATION (US) | 2006-07-04 | — | — | US | disclosed |
| CN-1257896-C | Funcitonal molecule material containing four tertiary amine branches and preparation method | UNIV FUDAN (CN) | 2006-05-31 | — | — | CN | disclosed |
| WO-2006000420-A1 | PYRIMIDINE UREA DERIVATIVES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2006-01-05 | — | — | WO | disclosed |
| WO-2005032548-A1 | SUBSTITUTED BENZAZOLES AND USE THEREOF AS INHIBITORS OF RAF KINASE | CHIRON CORPORATION (US) | 2005-04-14 | — | — | WO | disclosed |
| EP-1499311-A1 | SUBSTITUTED BENZAZOLES AND USE THEREOF AS RAF KINASE INHIBITORS | Chiron Corporation (US) | 2005-01-26 | — | — | EP | disclosed |
| CN-1539833-A | Funcitonal molecule material containing four tertiary amine branches and preparation method | 复旦大学 | 2004-10-27 | — | — | CN | disclosed |
| US-20040122237-A1 | Substituted benzazoles and methods of their use as inhibitors of Raf kinase | NOVARTIS AG (CH) | 2004-06-24 | — | — | US | disclosed |
| US-20040087626-A1 | Substituted benz-azoles and methods of their use as inhibitors of Raf kinase | NOVARTIS AG (CH) | 2004-05-06 | — | — | US | disclosed |
| WO-2003082272-A1 | SUBSTITUTED BENZAZOLES AND USE THEREOF AS RAF KINASE INHIBITORS | CHIRON CORPORATION (US) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240009193-A1 | METHODS OF TREATING ACHONDROPLASIA | FGFR3, FGF2, FGF1 | SIRT6 289/4885POLB 1158/4885MAPT 3391/4885 |
| US-20040122237-A1 | Substituted benzazoles and methods of their use as inhibitors of Raf kinase | BRAF, RAF1, ARAF | SIRT6 3252/4885POLB 1655/4885MAPT 3948/4885 |
| US-20040087626-A1 | Substituted benz-azoles and methods of their use as inhibitors of Raf kinase | BRAF, RAF1, ARAF | SIRT6 3316/4885POLB 1501/4885MAPT 3981/4885 |
| US-12357632-B2 | Methods of treating cholangiocarcinoma | KRAS, SLC10A2, SLC10A1 | SIRT6 3001/4885POLB 1489/4885MAPT 4676/4885 |
| US-20250101002-A1 | DEUTERATED INFIGRATINIB COMPOUNDS | FGFR3, FGFR1, ABL1 | SIRT6 2990/4885POLB 564/4885MAPT 415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.